Anixa Biosciences (ANIX) EBIT Margin (2010 - 2023)

Anixa Biosciences' (ANIX) quarterly EBIT Margin came in at 1219.05% in Q2 2023, down 100.3% on a QoQ basis from 407700.0% in Q4 2021.

Anixa Biosciences (ANIX) EBIT Margin (2010 - 2023) Analysis & Trends

Anixa Biosciences (ANIX) has 11 years of EBIT Margin data on file, last reported at 1219.05% in Q2 2023.

Quarterly EBIT Margin changed N/A year-over-year to 1219.05% in Q2 2023, while the trailing twelve-month figure through Oct 2023 was 5268.42% (changed N/A YoY) and the FY2023 annual result came in at 5243.33%, changed N/A from the prior year.
EBIT Margin declined to 1219.05% in Q2 2023, from 407700.0% in the prior quarter.
In the past five years, EBIT Margin ranged from a high of 407700.0% in Q4 2021 to a low of 1219.05% in Q2 2023.
A 3-year average of 101252.09% and a median of 736.29% in 2019 frame the typical range for EBIT Margin.
The widest YoY moves for EBIT Margin: up 85050 bps in 2019, down 85050 bps in 2019.
Tracing ANIX's EBIT Margin over 3 years: stood at 1037.29% in 2019, then surged by 39404 bps to 407700.0% in 2021, then plunged by 100 bps to 1219.05% in 2023.
The last three EBIT Margin figures came in at 1219.05% (Q2 2023), 407700.0% (Q4 2021), and 435.28% (Q1 2021), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBIT Margin (Qtr)
1	Vertex Pharmaceuticals	138.93 Bn	131.07 Bn	2.84 Bn	37.40%
2	Regeneron Pharmaceuticals	85.91 Bn	77.92 Bn	3.93 Bn	30.15%
3	Argenx Se	64.98 Bn	59.80 Bn	1.37 Bn	32.54%
4	Moderna	58.86 Bn	53.72 Bn	52.00 Mn	-562.07%
5	BeOne Medicines	42.03 Bn	36.93 Bn	1.53 Bn	19.06%
6	Alnylam Pharmaceuticals	31.54 Bn	28.23 Bn	992.69 Mn	17.93%
7	BioNTech SE	27.88 Bn	9.49 Bn	668.28 Mn	-35.57%
8	Insmed	27.44 Bn	26.28 Bn	358.27 Mn	-0.36%
9	Royalty Pharma	27.35 Bn	26.51 Bn	-	19.75%
10	Anixa Biosciences	124.96 Mn	124.96 Mn	-	-

Download Data